Quick Answer
HCW Biologics Inc. reported Net Income Loss of -$7.96 million for the year ending 2025.
- HCW Biologics Inc. showed an increase of +73.5% in Net Income Loss from 2024 to 2025.
- This data is from HCW Biologics Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$2.38 million | Q2 2020: -$2.78 million | Q3 2020: -$2.71 million | Q1 2021: -$2.84 million | Q2 2021: -$2.75 million | Q3 2021: -$4.09 million | Q1 2022: -$2.06 million | Q2 2022: -$3.51 million | Q3 2022: -$3.91 million | Q1 2023: -$5.07 million | Q2 2023: -$4.30 million | Q3 2023: -$4.94 million | Q1 2024: -$7.47 million | Q2 2024: -$15.28 million | Q3 2024: -$3.90 million | Q1 2025: -$2.20 million | Q2 2025: -$1.93 million | Q3 2025: -$4.55 million.
- Over the full 6 years of available data (2020 to 2025), HCW Biologics Inc.'s Net Income Loss has declined by 37.2%.
- Historical annual values: Fiscal year 2025: -$7.96 million | Fiscal year 2024: -$30.02 million | Fiscal year 2023: -$24.99 million | Fiscal year 2022: -$14.90 million | Fiscal year 2021: -$12.86 million | Fiscal year 2020: -$5.80 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: